The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia
Abstract
:1. Introduction
2. Standard Management of AIHA
3. Novel Agents and AIHA
4. Idelalisib
5. Ibrutinib
6. Venetoclax
7. Discussion
8. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Smith, A.; Howell, D.; Patmore, R.; Jack, A.S.; Roman, E.P. Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network. Br. J. Cancer 2011, 105, 1684–1692. [Google Scholar] [CrossRef] [Green Version]
- Dearden, C. Disease-Specific Complications of Chronic Lymphocytic Leukemia. Hematology 2008, 2008, 450–456. [Google Scholar] [CrossRef] [Green Version]
- Visco, C.; Barcellini, W.; Maura, F.; Neri, A.; Cortelezzi, A.; Rodeghiero, F. Autoimmune cytopenias in chronic lymphocytic leukemia. Am. J. Hematol. 2014, 89, 1055–1062. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hallek, M.; Cheson, B.D.; Catovsky, D.; Caligaris-Cappio, F.; Dighiero, G.; Döhner, H.; Hillmen, P.; Keating, M.; Montserrat, E.; Chiorazzi, N.; et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018, 131, 2745–2760. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hill, Q.A.; Stamps, R.; Massey, E.; Grainger, J.D.; Provan, D.; Hill, A.; Haematology, T.B.S.F. The diagnosis and management of primary autoimmune haemolytic anaemia. Br. J. Haematol. 2016, 176, 395–411. [Google Scholar] [CrossRef]
- Hill, Q.A.; Hill, A.; Berentsen, S. Defining autoimmune hemolytic anemia: A systematic review of the terminology used for diagnosis and treatment. Blood Adv. 2019, 3, 1897–1906. [Google Scholar] [CrossRef] [Green Version]
- Bröker, B.M.; Klajman, A.; Youinou, P.; Jouquan, J.; Worman, C.P.; Murphy, J.; MacKenzie, L.; Quartey-Papafio, R.; Blaschek, M.; Collins, P.; et al. Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J. Autoimmun. 1988, 1, 469–481. [Google Scholar] [CrossRef]
- Quinquenel, A.; Al Nawakil, C.; Baran-Marszak, F.; Eclache, V.; Letestu, R.; Khalloufi, M.; Boubaya, M.; Le Roy, C.; Varin-Blank, N.; Delmer, A.; et al. Old DAT and new data: Positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients. Am. J. Hematol. 2014, 90, E5–E8. [Google Scholar] [CrossRef] [PubMed]
- Barcellini, W.; Fattizzo, B.; Zaninoni, A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev. Clin. Immunol. 2018, 14, 857–872. [Google Scholar] [CrossRef] [PubMed]
- Rogers, K.A.; Woyach, J.A. Secondary autoimmune cytopenias in chronic lymphocytic leukemia. Semin. Oncol. 2016, 43, 300–310. [Google Scholar] [CrossRef]
- D’Arena, G.; Laurenti, L.; Capalbo, S.; D’Arco, A.M.; De Filippi, R.D.; Marcacci, G.; Di Renzo, N.; Storti, S.; Califano, C.; Vigliotti, M.L.; et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am. J. Hematol. 2006, 81, 598–602. [Google Scholar] [CrossRef]
- Herishanu, Y.; Levi, S.; Kamdjou, T.; Bornstein, Y.; Ram, R.; Benyamini, N.; Varon, D.; Avivi, I.; Perry, C. Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br. J. Haematol. 2021, 192, e1–e4. [Google Scholar] [CrossRef]
- Berentsen, S. How I treat cold agglutinin disease. Blood 2021, 137, 1295–1303. [Google Scholar] [CrossRef] [PubMed]
- Pamuk, G.E.; Turgut, B.; Demir, M.; Tezcan, F.; Vural, Ö. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia. Am. J. Hematol. 2006, 81, 631–633. [Google Scholar] [CrossRef] [PubMed]
- Jäger, U.; Barcellini, W.; Broome, C.M.; Gertz, M.A.; Hill, A.; Hill, Q.A.; Jilma, B.; Kuter, D.J.; Michel, M.; Montillo, M.; et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2020, 41, 100648. [Google Scholar] [CrossRef]
- Rossignol, J.; Michallet, A.-S.; Oberic, L.; Picard, M.H.; Garon, A.; Willekens, C.; Dulery, R.; Leleu, X.; Cazin, B.; Ysebaert, L. Rituximab–cyclophosphamide–dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia 2010, 25, 473–478. [Google Scholar] [CrossRef] [Green Version]
- Kaufman, M.; Limaye, S.A.; Driscoll, N.; Johnson, C.; Caramanica, A.; Lebowicz, Y.; Patel, D.; Kohn, N.; Rai, K. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk. Lymphoma 2009, 50, 892–899. [Google Scholar] [CrossRef] [PubMed]
- Quinquenel, A.; Willekens, C.; Dupuis, J.; Royer, B.; Ysebaert, L.; De Guibert, S.; Michallet, A.-S.; Feugier, P.; Guieze, R.; Levy, V.; et al. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS). Am. J. Hematol. 2014, 90, 204–207. [Google Scholar] [CrossRef] [PubMed]
- Weiss, R.B.; Freiman, J.; Kweder, S.L.; Diehl, L.F.; Byrd, J.C. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 1998, 16, 1885–1889. [Google Scholar] [CrossRef] [PubMed]
- Feld, J.; Arnason, J.; Brien, K.O.A.; Nahas, M. Hot and Cold: A Concurrent Warm and Cold Autoimmune Hemolytic Anemia in B-cell Prolymphocytic Leukemia. Acta Haematol. 2019, 141, 222–224. [Google Scholar] [CrossRef] [PubMed]
- Godet, S.; Quinquenel, A.; Dartigeas, C.; Ysebaert, L.; Dupuis, J.; Ohanyan, H.; Collignon, A.; Gilardin, L.; Leprêtre, S.; Dilhuydy, M.-S.; et al. Kinase Inhibitors (ibrutinib or idelalisib) in the Management of Chronic Lymphocytic Leukemia-Associated Autoimmune Cytopenia: A Retrospective Study of the French Innovative Leukemia Organization (FILO). Blood 2018, 132, 3152. [Google Scholar] [CrossRef]
- Garcia-Horton, A.; St Bernard, R.; Lazo-Langner, A.; Xenocostas, A.; Mangel, J.; Howson-Jan, K.; Lam, S.; Hsia, C.C. Safe Start of Ibrutinib in Patients with Chronic Lymphocytic Leukemia and Uncontrolled Autoimmune Hemolytic Anemia. Blood 2018, 132, 5560. [Google Scholar] [CrossRef]
- Cavazzini, F.; Lista, E.; Quaglia, F.M.; Formigaro, L.; Cavallari, M.; Martinelli, S.; Rigolin, G.M.; Foa, R.; Cuneo, A. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. Leuk. Lymphoma 2016, 57, 2685–2688. [Google Scholar] [CrossRef] [PubMed]
- Hampel, P.J.; Larson, M.C.; Kabat, B.; Call, T.G.; Ding, W.; Kenderian, S.S.; Bowen, D.; Boysen, J.; Schwager, S.M.; Leis, J.F.; et al. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. Br. J. Haematol. 2018, 183, 421–427. [Google Scholar] [CrossRef] [Green Version]
- Vitale, C.; Ahn, I.E.; Sivina, M.; Ferrajoli, A.; Wierda, W.G.; Estrov, Z.; Konoplev, S.N.; Jain, N.; O’Brien, S.; Farooqui, M.; et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 2016, 101, e254–e258. [Google Scholar] [CrossRef] [Green Version]
- Montillo, M.; O’Brien, S.; Tedeschi, A.; Byrd, J.C.; Dearden, C.; Gill, D.; Brown, J.R.; Barrientos, J.C.; Mulligan, S.P.; Furman, R.R.; et al. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Blood Cancer J. 2017, 7, e524. [Google Scholar] [CrossRef]
- De Lacerda, M.P.; Guedes, N.R.; Yamakawa, P.E.; Pereira, A.D.; Da Fonseca, A.R.B.M.; De Chauffaille, M.L.L.F.; Goncalves, M.V.; Yamamoto, M.; Rodrigues, C.A. Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with (del17p). Ann. Hematol. 2017, 96, 1577–1578. [Google Scholar] [CrossRef] [PubMed]
- Gordon, M.J.; Maldonado, E.; Danilov, A.V. Refractory Autoimmune Cytopenias Treated With Venetoclax. HemaSphere 2019, 3, e202. [Google Scholar] [CrossRef]
- Tsang, M.; Parikh, S.A. A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia. Curr. Hematol. Malign. Rep. 2017, 12, 29–38. [Google Scholar] [CrossRef] [PubMed]
- Advani, R.H.; Buggy, J.J.; Sharman, J.P.; Smith, S.M.; Boyd, T.E.; Grant, B.; Kolibaba, K.S.; Furman, R.R.; Rodriguez, S.; Chang, B.Y.; et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies. J. Clin. Oncol. 2013, 31, 88–94. [Google Scholar] [CrossRef]
- Dubovsky, J.A.; Beckwith, K.A.; Natarajan, G.; Woyach, J.A.; Jaglowski, S.; Zhong, Y.; Hessler, J.D.; Liu, T.-M.; Chang, B.Y.; Larkin, K.M.; et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013, 122, 2539–2549. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Manda, S.; Dunbar, N.; Marx-Wood, C.R.; Danilov, A.V. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. Br. J. Haematol. 2015, 170, 734–736. [Google Scholar] [CrossRef] [Green Version]
- Galinier, A.; Delwail, V.; Puyade, M. Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma. Case Rep. Oncol. 2017, 10, 127–129. [Google Scholar] [CrossRef]
- Rider, T.G.; Grace, R.J.; Newman, J.A. Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia. Br. J. Haematol. 2016, 173, 326–327. [Google Scholar] [CrossRef] [PubMed]
- Visco, C.; Novella, E.; Peotta, E.; Paolini, R.; Giaretta, I.; Rodeghiero, F. Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. Haematologica 2010, 95, 1230–1232. [Google Scholar] [CrossRef] [PubMed]
- Byrd, J.C.; Wierda, W.G.; Schuh, A.; Devereux, S.; Chaves, J.M.; Brown, J.R.; Hillmen, P.; Martin, P.; Awan, F.T.; Stephens, D.M.; et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: Updated phase 2 results. Blood 2020, 135, 1204–1213. [Google Scholar] [CrossRef]
- Roberts, A.W.; Davids, M.S.; Pagel, J.M.; Kahl, B.S.; Puvvada, S.D.; Gerecitano, J.F.; Kipps, T.J.; Anderson, M.A.; Brown, J.R.; A Gressick, L.; et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2016, 374, 311–322. [Google Scholar] [CrossRef]
- Stilgenbauer, S.; Eichhorst, B.; Schetelig, J.; Hillmen, P.; Seymour, J.F.; Coutre, S.; Jurczak, W.; Mulligan, S.P.; Schuh, A.; As-souline, S.; et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J. Clin. Oncol. 2018, 36, 1973–1980. [Google Scholar] [CrossRef]
- Fattizzo, B.; Barcellini, W. Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects. Front. Oncol. 2020, 9, 1435. [Google Scholar] [CrossRef]
- Seymour, J.F.; Kipps, T.J.; Eichhorst, B.; Hillmen, P.; D’Rozario, J.; Assouline, S.; Owen, C.; Gerecitano, J.; Robak, T.; De La Serna, J.; et al. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2018, 378, 1107–1120. [Google Scholar] [CrossRef]
- Fischer, K.; Al-Sawaf, O.; Bahlo, J.; Fink, A.-M.; Tandon, M.; Dixon, M.; Robrecht, S.; Warburton, S.; Humphrey, K.; Samoylova, O.; et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N. Engl. J. Med. 2019, 380, 2225–2236. [Google Scholar] [CrossRef] [PubMed]
- Fischer, K.; Bahlo, J.; Fink, A.M.; Goede, V.; Herling, C.D.; Cramer, P.; Langerbeins, P.; Von Tresckow, J.; Engelke, A.; Maurer, C.; et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. Blood 2016, 127, 208–215. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sharman, J.P.; Coutre, S.E.; Furman, R.R.; Cheson, B.D.; Pagel, J.M.; Hillmen, P.; Barrientos, J.C.; Zelenetz, A.D.; Kipps, T.J.; Flinn, I.W.; et al. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relaps. J. Clin. Oncol. 2019, 37, 1391–1402. [Google Scholar] [CrossRef] [PubMed]
Treatment | Line for AIHA | n of Patients | ORR (%) | DOR (Months) | Reference |
---|---|---|---|---|---|
R-Idelalisib/Ibrutinib * | 1–6 | 12/16 | 92/87.5 | 26.8 | Godet S et al. 2018 [20] |
R-Idelalisib + PDN | 1 | 1 | NA | 3 | Feld J et al. 2019 [21] |
Ibrutinib | 2 | 5 | 100 | 32.5 | Garcia-Horton A et al. 2018 [22] |
Ibrutinib | 5 | 1 | NA | 12 | Cavazzini et al. 2016 [23] |
Ibrutinib ** | >1 | 29 | 67 | 29 | Hampel PJ et al. 2018 [24] |
Ibrutinib +/− Rituximab * | 1–4 | 8 | 75 | 17.6 | Vitale C et al. 2016 [25] |
Ibrutinib +/− steroids * | 1–2 | 21 | NA | 17.5 | Montillo M et al. 2017 [26] |
Venetoclax | 4 | 1 | NA | 10 | Lacerda MP et al. 2017 [27] |
Venetoclax * | 3 | 2 | NA | 6 | Gordon MJ et al. 2019 [28] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Noto, A.; Cassin, R.; Mattiello, V.; Reda, G. The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia. J. Clin. Med. 2021, 10, 2064. https://doi.org/10.3390/jcm10102064
Noto A, Cassin R, Mattiello V, Reda G. The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia. Journal of Clinical Medicine. 2021; 10(10):2064. https://doi.org/10.3390/jcm10102064
Chicago/Turabian StyleNoto, Alessandro, Ramona Cassin, Veronica Mattiello, and Gianluigi Reda. 2021. "The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia" Journal of Clinical Medicine 10, no. 10: 2064. https://doi.org/10.3390/jcm10102064
APA StyleNoto, A., Cassin, R., Mattiello, V., & Reda, G. (2021). The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia. Journal of Clinical Medicine, 10(10), 2064. https://doi.org/10.3390/jcm10102064